V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Vanda Pharmaceuticals Executive Compensation (FY25)

VNDA · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Mihael Polymeropoulos
Latest say-on-pay support
=
June 4, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Vanda Pharmaceuticals

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (8-K): June 5, 2026
4 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Vanda Pharmaceuticals brief$1,500Get the executive brief
Velarion Member, one year
222 figures on this page: 220 cited to the filing that reported them, 2 calculated from figures it prints. See the citations

More on Vanda Pharmaceuticals

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Mihael Polymeropoulos: $3,896,241 → $3,851,468 (1.1% lower)
Say-on-pay support: 73.9% → 91.8% (17.9 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Vanda Pharmaceuticals' chief executive and what were they paid?
Total compensation for Mihael Polymeropoulos, President, Chief Executive Officer and Chairman of the Board, came to $3,851,468 in fiscal 2025. Compared with the $3,896,241 reported for fiscal 2024, Polymeropoulos' total was 1.1% lower.
What was Vanda Pharmaceuticals' say-on-pay result?
Shareholders supported the say-on-pay proposal with 91.8% of votes cast for or against in favor at the meeting held June 4, 2026 for fiscal 2025.
Which companies are in Vanda Pharmaceuticals' peer group?
The disclosed peer group includes ACADIA Pharmaceuticals, Agios Pharmaceuticals, Amarin Corporation, Amicus Therapeutics and Corcept Therapeutics, among others. The 2026 Compensation Peer Group names Akebia Therapeutics, Arcturus Therapeutics Holdings, Axsome Therapeutics, Heron Therapeutics and Rigel Pharmaceuticals.
What is Vanda Pharmaceuticals' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 23.1:1, against median employee compensation of $166,623.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mihael Polymeropoulos
President and Chief Executive Officer
◇—◇◇◇—◇◇
Joakim Wijkstrom
Senior Vice President, Chief Marketing Officer
◇—◇◇◇—◇◇
Timothy Williams
Senior Vice President, General Counsel and Secretary
◇—◇◇◇—◇◇
Gunther Birznieks
Senior Vice President, Business Development
◇—◇◇◇—◇◇
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mihael Polymeropoulos
President, Chief Executive Officer and Chairman of the Board
◇—◇◇◇—◇◇
Timothy Williams
Senior Vice President, General Counsel and Secretary
◇—◇◇◇—◇◇
Gunther Birznieks
Senior Vice President, Business Development
◇—◇◇◇—◇◇
Joakim Wijkstrom
Senior Vice President, Chief Marketing Officer
◇—◇◇◇—◇◇
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mihael Polymeropoulos
President, Chief Executive Officer and Chairman of the Board
◇—◇—◇—◇◇
Timothy Williams
Senior Vice President, General Counsel and Secretary
◇—◇—◇—◇◇
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
◇—◇—◇—◇◇
Gunther Birznieks
Senior Vice President, Business Development
◇—◇—◇—◇◇
Joakim Wijkstrom
Senior Vice President, Chief Marketing Officer
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mihael Polymeropoulos
President, Chief Executive Officer and Chairman of the Board
◇—◇—◇—◇◇
Joakim Wijkstrom
Senior Vice President, Chief Marketing Officer
◇—◇—◇—◇◇
Timothy Williams
Senior Vice President, General Counsel and Secretary
◇—◇—◇—◇◇
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
◇—◇—◇—◇◇
Gunther Birznieks
Senior Vice President, Business Development
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Gunther BirznieksRSU◇——◇——◇
Joakim WijkstromRSU◇——◇——◇
Kevin MoranRSU◇——◇——◇
Mihael H. PolymeropoulosRSU◇——◇——◇
Timothy WilliamsRSU◇——◇——◇
Fiscal 2022, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Gunther BirznieksRSU◇◇——
Option◇—◇2/15/2033
RSU◇◇——
Option◇—◇2/27/2032
RSU◇◇——
RSU◇◇——
Timothy WilliamsRSU◇◇——
RSU◇◇——
Option◇—◇2/15/2033
RSU◇◇——
RSU◇◇——
Option◇—◇2/27/2032
Mihael PolymeropoulosRSU◇◇——
RSU◇◇——
Option◇—◇2/15/2033
RSU◇◇——
RSU◇◇——
Option◇—◇2/27/2032
Kevin MoranOption◇—◇2/27/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/15/2033
Joakim WijkstromOption◇—◇2/27/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/15/2033
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard W. Dugan
Lead independent director
◇◇————◇
Anne Sempowski Ward
◇◇————◇
Phaedra S. Chrousos
◇◇————◇
Tage Honoré
◇◇————◇
Stephen Ray Mitchell
◇◇————◇
Mihael H. Polymeropoulos and Charles C. Duncan served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals ACAD
  • Agios Pharmaceuticals AGIO
  • Amarin Corporation AMRN
  • Amicus Therapeutics FOLD
  • Corcept Therapeutics CORT
  • Enanta Pharmaceuticals ENTA
  • Intra-Cellular Therapies ITCI
  • Ironwood Pharmaceuticals IRWD
  • Lexicon Pharmaceuticals LXRX
  • Omeros Corporation OMER
  • Pacira BioSciences PCRX
  • Sage Therapeutics SAGE
  • Supernus Pharmaceuticals SUPN
  • Travere Therapeutics TVTX
2026 Compensation Peer Group
  • Akebia Therapeutics AKBA
  • Arcturus Therapeutics Holdings ARCT
  • Axsome Therapeutics AXSM
  • Heron Therapeutics HRTX
  • Rigel Pharmaceuticals RIGL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 4, 2026=◇◇◇
2024June 5, 2025=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Mihael Polymeropoulos (President, Chief Executive Officer and Chairman of the Board), FY2025 total compensation $3,851,468 (base salary $965,655) [exec_comp, SEC accession 0001628280-26-026893, filed 2026-04-23]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Vanda Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Vanda Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Vanda Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Vanda Pharmaceuticals' disclosed peer group is defensible, who names Vanda Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
222 figures on this page: 220 cited to the filing that reported them, 2 calculated from figures it prints.
220 cited to the filing
2 calculated from the filing

Documents cited

  1. 0001628280-26-041298
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001628280-26-026893
    2025 Director Compensation · 2025 Summary Compensation Table · Compensation of Directors · Outstanding Equity Awards at 2025 Year-End
  3. 0001628280-25-029678
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001628280-25-019987
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Vanda Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/VNDA (accessed 2026).
Short form: data: Velarion

The paid brief for Vanda Pharmaceuticals

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Vanda Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Vanda Pharmaceuticals discloses

The companies named in VNDA's own disclosed peer group.

ACADIA PharmaceuticalsAgios PharmaceuticalsAmarin CorporationAmicus TherapeuticsCorcept TherapeuticsEnanta PharmaceuticalsIntra-Cellular TherapiesIronwood PharmaceuticalsLexicon PharmaceuticalsOmeros CorporationPacira BioSciencesSage TherapeuticsSupernus PharmaceuticalsTravere TherapeuticsAkebia TherapeuticsArcturus Therapeutics HoldingsAxsome TherapeuticsHeron TherapeuticsRigel Pharmaceuticals

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy